The Group is a vertically integrated specialty pharmaceutical group that specializes in manufacturing, marketing and selling branded prescriptions, non-prescription Western medicines and proprietary Chinese medicine products, including proprietary Chinese medicine injections, for the Chinese market. The Group's products are diversified, including 28 types of drugs currently produced and sold to meet the huge medical demand in China, that is, drugs used to relieve symptoms such as respiratory, cardiovascular, gastroenterology, infectious diseases, and cancer. The Group's main products include 14 different Western medicines and 14 kinds of proprietary Chinese medicine products. Of these, 22 require a doctor's prescription, while the remaining 6 are non-prescription drugs, which can be used even without a doctor's prescription. These main products are part of the Group's diversified product portfolio. A total of 125 products in the product portfolio have been approved and registered by the State Food and Drug Administration, and the Group also has the required production technology and production capacity. Once the market demand for individual products is mature and reasonable profits can be expected, they can be produced and sold at any time. Based on internal market research, the Group selects products that are expected to have strong market demand and high profit potential to carry out production and sales. Currently, the 28 main products selected for production and sale are all products that the Group believes have higher profit potential than other products in the portfolio. The Group's core strengths include the Group's “Sanai” brand (which is widely recognized for its high quality and good reputation), and the Group's production and marketing platform (which produces and sells a diversified combination of 14 different prescription Western medicines and 14 proprietary Chinese medicines). The Group plans to use these advantages to increase the market share of currently marketed products and launch new products in key target markets.
No Data